Ultrasound-triggered on Demand Lidocaine Release Relieves Postoperative Pain

Xiaohong Chen  
Soochow University Affiliated No 1 People\’s Hospital: First Affiliated Hospital of Soochow University

Jianfeng Zhang  
Nantong Tumor Hospital

Yan Yu  
Nantong Tumor Hospital

Haoran Wang  
Nantong Tumor Hospital

Genshan Ma  
Nantong Tumor Hospital

Di Wang  
Nantong Tumor Hospital

Donglin Xia  
Nantong University

Hanzhong Cao  
Nantong Tumor Hospital

Jianping Yang (✉️ YangJP1956@126.com)  
Soochow University Affiliated No 1 People\’s Hospital: First Affiliated Hospital of Soochow University

https://orcid.org/0000-0002-9498-472X

Research article

Keywords: Ultrasound-triggered, Postoperative pain, Lidocaine, On-demand release, Erythrocytes

Posted Date: November 30th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1060260/v1

License: ☇️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

Safe and noninvasive on-demand relief is a crucial and effective treatment for postoperative pain because it considers variable timing and intensity of anesthetics. Ultrasound modulation is a promising technique for this treatment because it allows convenient timed and noninvasive controlled drug release.

Methods

We created an ultrasound-triggered lidocaine (Lido) release platform using an amino acid hydrogel functioning as three dimensional (3D) scaffold material (Lido-PPIX@ER hydrogel). Optimal preparation conditions and ultrasound-triggered parameters were evaluated. In the postoperative pain SD rat model, the Lido-PPIX@ER hydrogel or free lidocaine was administered by subcutaneous injection immediately after making the paw incision. Mechanical hypersensitivity was assessed using calibrated von Frey filaments after an individualized (highly variable) ultrasound-triggered process. The safety of the treatment was also evaluated.

Results

The Lido-PPIX@ER hydrogel allows control of the timing, intensity and duration of lidocaine (Lido) to relieve postoperative pain. The hydrogel releases Lido due to the elevated reactive oxygen species (ROS) levels generated by PPIX under ultrasound triggering. The optimal ultrasound parameter (0.3 W/cm², 30 s) was chosen for in vitro and in vivo studies. The Lido-PPIX@ER hydrogel (with lidocaine, 5.6 mg/mL) under individualized ultrasound triggering (every 2 h in the first 12 h, every 4 h for the next 36 h, and then every 6 h until 72 h postsurgery) released lidocaine and provided effective analgesia for more than 72 h. Additionally, the withdrawal threshold was higher than that in the control group at all time points measured. The hydrogel showed repeatable and adjustable ultrasound-triggered nerve blocks in vivo, the duration of which depended on the extent and intensity of insonation. On histopathology, no systemic effect or tissue reaction was observed in the ultrasound-triggered Lido-PPIX@ER hydrogel-treated group.

Conclusions

The Lido-PPIX@ER hydrogel with individualized (highly variable) ultrasound triggering is a convenient and effective method that offers timed and spatiotemporally controlled Lido release to manage postoperative pain.

Background

Postoperative pain management, particularly acute postoperative pain analgesia, remains a leading clinical problem [1, 2]. Without personalized, adjustable and convenient regional anesthesia, many patients experience intolerable pain. Studies have reported that 10-50% of patients undergoing surgery experience postoperative pain lasting more than 1 month, and 2-10% of these patients continue to
experience moderate to severe chronic pain [3]. Although many new devices for postoperative pain have been developed, inadequate postoperative analgesia occurs because the anesthetic cannot meet the on-demand requirements [4–6]. Inadequate management of postoperative pain can lead to severe consequences, such as poor immediate postoperative effects, prolonged hospital stays, poor patient satisfaction, and increased burden on patients and health systems [1, 7, 8]. Thus, variability in the patients’ ability to modulate pain has clinical application in the control of postoperative pain.

Remotely triggered drug release systems have been developed that can meet the need to regulate pharmacological effects in a timely manner [9–11]. Ultrasound is already commonly used in both hospital and family therapy for diagnostic and therapeutic practice [12]. Ultrasound is noninvasive and can penetrate deep into tissues [4]. It can be applied in a focused manner to minimize the energy applied to the surrounding, nontargeted tissues. Many of the current ultrasound-triggerable drug release systems, such as micelles, liposomes, composites and hybrid materials, are responsive to the thermal and mechanical effects of ultrasound waves [13–16]. To improve the effect of sonodynamic therapy, more sonosensitizers have been developed, such as protoporphyrin IX (PPIX) [4]. Ultrasound can induce sonochemistry—that is, the use of ultrasonic waves for chemical reactions in which sound sensitizers are activated by acoustic energy to generate reactive oxygen species (ROS). Remote-controlled ROS generation has been widely explored to trigger drug release [17].

Erythrocytes (ER), which can deliver various drugs, are attractive systems with adequate lifespans, large internal capacities, and good biocompatibility [18–20]. Remote laser-controlled drug delivery systems, showing spatiotemporally controlled drug release, allow on-demand drug release without invasive injury [21]. Photosensitisers generate reactive oxygen species (ROS) by laser irradiation, working as optical switches to be used in remote laser-controlled drug delivery systems [22]. Under remote stimulation, drugs are released into the bloodstream from the laser-regulated drug release system because of ROS generation, opening the ER phospholipid bilayer and triggering drug release. Once the remote stimulation disappears, ROS is no longer produced, and the generated ROS is scavenged by superoxide dismutase and catalase, leading to ROS exhaustion in the hydrogel [17]. The pores on the ER membrane are then closed to terminate the release behavior.

Inspired by the characteristics of sonodynamic therapy and erythrocytes as drug carriers, an injectable erythrocyte-inspired, ultrasound-activated hydrogel (Lido-PPIX@ER hydrogel) was reported (Scheme 1). In this system, ERs are used as reservoirs for both Lido and PPIX (Scheme 1A), and the deformed hydrogel can be subcutaneously injected into the body and function as a 3D scaffold containing Lido- and PPIX-loaded ER to improve their subcutaneous stability. This Lido-PPIX@ER hydrogel releases Lido because of the elevated content of reactive oxygen species (ROS) generated by PPIX under ultrasound. Conversely, ROS are scavenged without ultrasound irradiation and stop Lido release from the Lido-PPIX@ER hydrogel (Scheme 1B). Thus, an ultrasound-triggered anesthetic release system with remote-controlled timing and intensity is obtained to regulate postoperative pain on demand. Collectively, we highlight the potential of this ER-enabled on-demand nerve block system, which can use off-the-shelf ultrasound clinical
equipment and may ease the clinical transformation of on-demand drug delivery systems in postoperative pain management.

**Methods**

**Materials and animals**

Lidocaine hydrochloride (5 mL: 0.1 g) was obtained from Tiancheng Pharmaceutical (Hebei, China). Protoporphyrin IX (PPIX) and dialysis bags (molecular cutoff, 0.5 kDa) were obtained from Bomei Biotechnology (Hefei, China). Fluorescein isothiocyanate lidocaine (FITC-Lido) was provided by Qiyue Biological Technology (Xi’an, China). Fmoc-Phe and Phe2 were purchased from Yuanye Biotechnology (Shanghai, China). Lipase from *Pseudomonas fluorescens* (PFL) was provided by Aladdin Industrial Corporation (Shanghai, China). An malondialdehyde (MDA) kit was obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). All other reagents were of reagent grade.

SPF Sprague–Dawley (SD) rats were purchased from the Experimental Animal Center of Nantong University. All the animals were housed at 24±2°C, 40-70% humidity, and a 12 h photoperiod.

**Preparation of the Lido-PPIX@ER hydrogel**

Fresh blood was collected from SD rats using an appropriate anticoagulant (heparin). ERs were normally centrifuged at 4°C and then washed with 10-15 mL of PBS solution at least three times. The hypotonic dialysis method was adopted to prepare the Lido-PPIX@ER. Briefly, PPIX was dissolved in 1 mL of dimethyl sulfoxide (DMSO). Next, lidocaine hydrochloride and PPIX were added to the ER suspension. The mixture was subjected to dialysis (molecular cut off, 0.5 kDa) before immersion in hypotonic buffer (72 mOsm/kg, pH 8) at 4°C for a set time and resealing buffer (550 mOsm/kg, pH 8) for 30 min at 37°C. Finally, free lidocaine hydrochloride and PPIX were removed using repeated centrifugation.

Hypotonic buffer was used to prepare Lido-PPIX@ER, comprising 15 mM NaH$_2$PO$_4$·2H$_2$O, 15 mM NaHCO$_3$, 2 mM ATP, 3 mM glutathione, 20 mM glucose, and 5 mM NaCl in 100 mL of distilled water, and the resealing buffer included 250 mM NaCl, 12.5 mM glucose, 12.5 mM sodium pyruvate, 12.5 mM inosine, 12.5 mM NaH$_2$PO$_4$·2H$_2$O, 0.63 mM adenine, and 550 mOsm/kg in 100 mL of distilled water [23].

The deformable peptide hydrogel was prepared as described previously [24]. Briefly, the substrates Fmoc-Phe and Phe$_2$ were suspended in 420 µL of 0.5 M NaOH. The final concentrations of the Fmoc-Phe derivative and Phe$_2$ were 11.3 mg/mL and 8.5 mg/mL, respectively. Next, 500 µL of Lido-PPIX@ER, 0.1 M catalase, and SOD were added and dispersed in the suspension using a magnetic stirrer. The pH (7.0) was adjusted using 0.1 M HCl, and a final volume of 3.5 mL was obtained. Next, 100 µL of 50 mg/mL of lipase solution was added to the substrate suspension, and incubation was performed in a controlled temperature bathtub (37°C) for up to 30 min.

**Characterization of the Lido-PPIX@ER hydrogel**
For SEM analysis, Lido-PPIX@ER and Lido-PPIX@ER hydrogel samples were prepared as follows. The samples were treated with 2.5% (v/v) glutaraldehyde in PBS (0.1 M, pH 7.4) for 3 h at 4 °C. Next, after washing with PBS, the samples were mixed with different ethanol solutions (60 to 100%) for 15 min at room temperature. All the samples were coated with a 10 nm thick gold film using a sputter coater, and the coated samples were examined using a JSM-6700F microscope (JEOL, Japan) in the secondary scattering and backscattering electron modes at a 10 keV electron acceleration voltage.

FITC-labeled lidocaine was tested in vitro. Images of ER-encapsulated FITC-Lido (green) and PPIX (red) were obtained using a Leica DM400 B LED (Leica, Germany) fluorescence microscope. LasX and Huygens were used for microscopy operation and data analysis, respectively.

The Lido-PPIX@ER was mixed with the amino acid hydrogel under stirring for 30 s using a vortex mixer, and then PFL was added. Photographs were taken at 2 and 8 min. The rheology experiment was performed using a rheometer at 37°C to determine the elastic modulus (G') of the formed gel. The inflammatory activity of the Lido-PPIX@ER hydrogel was evaluated as follows: 1.0 mL of Lido-PPIX@ER hydrogel was subcutaneously injected into the back of the rat, and blocks of skin tissue from the injection site were collected on the 3rd day and sliced. The anti-inflammatory activity was evaluated by imaging macrophages stained with rabbit anti-F4-80 fluorescent antibody. The sections were analyzed using a Leica SP8 STED instrument.

The weight fraction in percent vs. time and volume change of peptide hydrogel was tested as follows: After freeze-drying, the hydrogel was immediately weighed (W₀), the volume was measured (V₀), and the water absorption capacity of the samples was obtained. The wet specimens were weighed (W), and the volume (V) was measured at specified intervals after immersion in PBS at room temperature. The weight change was calculated as follows: weight fraction % = W/W₀×100%. The volume change was calculated as follows: volume fraction % = V/V₀×100%.

**In vitro release behavior of INS from the Lido-PPIX@ER hydrogel**

The lidocaine concentration was determined by LC-2030 series HPLC (Shimadzu Corporation, Japan). The analysis was performed using a Hypersil OD S2 C₁₈ 5 μm column (250 × 4.6 mm, Å). The mobile phase was methanol/ammonium dihydrogen phosphate 0.01 M (NH₄H₂PO₄) (25:75, v/v). The flow rate was set to 1.0 mL/min, and the detection was monitored at 220 nm.

The release behavior of the Lido-PPIX@ER hydrogel under different ultrasound powers (0-1 W/cm² for 60 s) was monitored. The lidocaine concentration was monitored because the Lido@ER hydrogel (without PPIX) and Lido-PPIX@ER hydrogel (with 10 mg/mL of lidocaine in the ER) were triggered by ultrasound (0.3 W/cm²) for approximately 180 s. The spatiotemporally controlled release behavior of the Lido-PPIX@ER hydrogel was examined as 0.3 W/cm² for repeated 30 s irradiation, and the assay was
replicated a minimum of five times. HPLC was used to measure the PPIX concentration in the supernatant.

**Singlet oxygen and MDA determination**

To analyze the laser irradiation-dependent release mechanism of the Lido-PPIX@ER hydrogel, singlet oxygen was labeled using a chemical probe (DCFH-DA; BestBio, Shanghai, China). The release at different time points was monitored based on fluorescence using a Leica DM400 B LED fluorescence microscope.

The malondialdehyde (MDA) concentration was measured using an MDA kit. The OD values of the measuring tube (OD$_m$), control tube (OD$_c$), standard tube (OD$_s$) and blank tube (OD$_b$) were measured at 533 nm.

The MDA concentration of Lido-PPIX@ER at different glucose concentrations was calculated as follows:

\[
\text{MDA (nmol/L)} = \frac{\text{OD}_m - \text{OD}_c}{\text{OD}_s - \text{OD}_b} \times \frac{\text{standardsubstanceconcentration}}{\text{proteininconcentration}}
\]

**Postoperative pain model**

The surgery was performed according to the procedure described by Brennan et al. [10]. In this model, a 1 cm incision was made on the plantar surface of the left hind paw under isoflurane anesthesia (2% isoflurane in 100% oxygen). The incision was started immediately beginning at the distal end of the heel and extended to the proximal end of the first set of footpads. Forceps were used to elevate the plantar muscle, and the incision was lengthwise. The wound was sutured with two mattress sutures using 5-0 silk. After surgery, the rats recovered from anesthesia in their cages. Wounds were checked for signs of dehiscence before the behavioral test.

**In vivo behavioral testing**

To assess the in vivo management of postoperative pain, Lido-PPIX@ER hydrogel was subcutaneously injected around the created wound in the postoperative pain model rats before solidifying. The rats were divided into 2 groups (n = 10 per group)—namely, the free Lido group (6 mg) and 1 mL Lido-PPIX@ER hydrogel (with 5.6 mg lidocaine) + ultrasound group (0.3 W/cm$^2$, 30 s).

The rats were placed in individual plastic chambers with a plastic mesh floor and allowed to acclimate to the environment for 30 min. The mechanical withdrawal threshold was measured using calibrated von Frey filaments (Stoelting, Wood Dale, IL). The filaments were applied vertically in the area adjacent to the wound for 5-6 s with slight bending of the filament. Withdrawal of the hind paw from the stimulus was scored as a positive response. As described previously, the updown method was used to identify tactile stimuli with a 50% likelihood of producing a withdrawal threshold [25].
Long-term postoperative pain management was administered as 30 s ultrasound irradiation (0.3 W/cm\(^2\), 30 s) every 2 h within 12 h after surgery, every 4 h from 12 to 48 h, and every 6 h from 48 to 72 h after surgery. The withdrawal threshold was determined after ultrasound triggering.

**Histological observation**

For histological evaluations, the postoperative pain model, treated with Lido-PPIX@ER hydrogel + ultrasound, was sacrificed to collect the skin tissue at the injection site and key organs, including heart, liver, kidney, lung, and spleen.

**Blood biochemistry index**

Following the administration of Lido-PPIX@ER hydrogel + ultrasound for 5 and 15 days, an automated biochemical analyzer (Trilogy, France) was used to determine liver function indices, including alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Likewise, the kidney function markers blood urea nitrogen (BUN), creatinine (Cr), and globulin (GLB) were also evaluated [26].

**Statistical analysis**

All values were reported as means ± SD unless stated otherwise. Statistical analysis was performed using SPSS 18.0 software. Multiple variables were compared using ANOVA, while two groups were compared using two-sample t-test. \( P < 0.05 \) was considered statistically significant.

**Results**

Preparation of Lido-PPIX@ER

In the present study, ERs were used as lidocaine carriers because of their high drug loading capacities and long \textit{in vivo} circulation features in vessels [27]. The lidocaine content inside Lido-PPIX@ER is a key factor that affects the therapeutic efficiency in postoperative pain. During the preparation of Lido-PPIX@ER, the ERs were first dispersed in a hypotonic solution to achieve a preswelling status to facilitate drug loading (Figure 1A). The ER carriers bulged and became enlarged, but maintained their original shape (concave disk-like). Subsequently, the Lido-PPIX@ER was dispersed in a hypertonic solution for reannealing. The ER carriers became smaller, and the fovea of the ERs became enlarged. Finally, the Lido-PPIX@ER was dispersed in isotonic solution for resealing. Because the ER cell membrane comprises phospholipid bilayers, the high tension (hyposmotic conditions) loosened the bilayers and allowed the drugs to enter (Figure 1B). Similarly, the bilayers became compact under hypertonic reannealing and returned to normal under isotonic resealing. Thus, we established a practical lidocaine-loaded ER system.

To achieve a practical lidocaine-loaded erythrocyte system, the optimal loading condition was first challenged using a procedure involving the lidocaine concentration, dialysis time and temperature. The loading content of lidocaine increased with increasing Lido concentration until it approached 15 mg/mL (Figure 1C). Extending the incubation time also resulted in more Lido entering ERs to reach equilibrium.
(Figure 1D). The temperature of 4°C was selected as the best reaction temperature in hypotonic dialysis (Figure 1E).

In the present study, PPIX was loaded inside the ER to act as an ultrasound-activated switch to control lidocaine release. The resulting decrease in the lidocaine concentration in ERs (Figure 2A) indicated that PPIX and ER bind competitively to lidocaine. An optimized PPIX concentration (0.3%) was adopted to achieve a high lidocaine loading content without compromising the Lido-loading efficiency. To further demonstrate that lidocaine and PPIX were enclosed within ERs, the loading of lidocaine and PPIX was characterized by fluorescence imaging (Figure 2B). FITC-labeled PPIX (green) and lidocaine (red) were both observed in ERs. The overlapping image of Lido and PPIX demonstrated the successful encapsulation of lidocaine and PPIX inside Lido-PPIX@ER.

Even after the loading of lidocaine and PPIX, ERs maintained their original shape (concave disk-like) and size. Additionally, hematological parameters showed no significant differences between the native ER and Lido-PPIX@ER, such as the RBC number (RBC), hematocrit (HCT), mean corpuscular volume (MCV), red blood cell distribution width (RDW), hemoglobin (Hb), and mean corpuscular hemoglobin (MCH) (Figure 2C). These results suggested that the encapsulation of Lido and PPIX did not alter the biological properties of the ERs.

Preparation of the Lido-PPIX@ER hydrogel

The ER drug carriers were administered subcutaneously and scavenged by macrophages [23]. To extend their lifetime in vivo, the Lido-PPIX@ER were embedded in a stable scaffold comprising an amino acid hydrogel, which could be subcutaneously implanted. *Pseudomonas fluorescens* (PFL) was used to catalyze the formation of a peptide bond between Fmoc-Phe and Phe$_2$ at 37°C. The mechanical properties of this hydrogel obtained at different reaction times are shown in Figure 3A. After 8 min, the highest mechanical property was reached and maintained a constant value with extension of the reaction time. The lipase-catalyzed reaction rapidly changed the reaction medium from solution to gel, enhancing the mechanical properties. When the reaction was completed, the hydrogel was no longer formed, resulting in a constant mechanical property.

Mixing Lido-PPIX@ER and amino acids (1:1, vol/vol) formed a cohesive network (Lido-PPIX@ER hydrogel) following the addition of lipase (PFL). After lipase addition, the mixture of Lido-PPIX@ER and PFL shifted from liquid to a homogeneous gel state (Figure 3B). Next, the changes from liquid to gel in vivo were examined. The peptide hydrogel was subcutaneously injected within 2 min. Ten minutes later, the mixture and PFL also shifted from liquid to a homogeneous gel state in vivo (Figure 3C).

The hydrogel worked as a scaffold to support the Lido-PPIX@ER and prolonged the action time. We hypothesized that the hydrogel could support the structure of Lido-PPIX@ER because a small change in the volume of the Lido-PPIX@ER hydrogel was observed during the following 3 days (Figure 3D). The hydrogel swelled in PBS, resulting in a slight increase in weight in the first 6 h. Next, it reached weight balance and maintained a constant weight for more than 3 d (Figure 3E).
This transforming ability ensured that the Lido-PPIX@ER hydrogel was injected into a mold to obtain a stable 3D structure. The SEM image in Figure 3F illustrates the porous structure of this obtained amino acid hydrogel comprising a 3D network with microchannels. ERs, exhibiting a typical concave disk structure similar to normal ERs, were still clearly observed in this hydrogel. As envisioned, the Lido in the Lido-PPIX@ER hydrogel exhibited excellent stability in vitro because most of the Lido still exited the ERs (Figure 3G). Combining the results in Figure 1, we confirm the successful loading of ERs.

Good compatibility, without an inflammatory-like response, is a vital feature of subcutaneous scaffolds to prevent macrophage infiltration, preventing the early destruction of drug-loaded ER [28]. The infiltrated macrophages in the subcutaneous tissues after the hydrogel implant were labeled with f4/80 (green) and are shown in Figure 3H. Compared with the direct injection of Lido-PPIX@ER, the injection of Lido-PPIX@ER hydrogel did not induce significant infiltration of macrophages even after 5 d. This finding partly demonstrated that the Lido-PPIX@ER hydrogel would not induce inflammation in vivo.

Ultrasound-triggered in vitro release of Lido from Lido-PPIX@ER hydrogel

We expected that when the Lido-PPIX@ER hydrogel is triggered by ultrasound, PPIX will produce ROS, which consequently destroy the integrity of the ER membrane, leading to Lido release. To confirm the ultrasound-triggerable response leakage of Lido, the release of Lido from the Lido-PPIX@ER hydrogel was monitored by ultrasound from 0 to 1 W/cm² for 60 s (Figure 4A). The burst release of Lido was observed when the ultrasound power was greater than 0.3 W/cm² (P<0.01), while almost no Lido was released when the power was off. This result demonstrated that ultrasound (0.3 W/cm²) was effective in regulating Lido release from the Lido-PPIX@ER hydrogel.

By contrast, almost no Lido was released from the Lido@ER hydrogel (without PPIX) with/without ultrasound or the Lido-PPIX@ER hydrogel without ultrasound (Figure 4B). Interestingly, Lido release from the Lido-PPIX@ER hydrogel could be accelerated with the extension of ultrasound (Figure 4C). To evaluate the responsible release behavior of the Lido-PPIX@ER hydrogel, the Lido concentration was monitored when the ultrasound was cyclically turned on and off every 30 s. Lido released from the 1 mL Lido-PPIX@ER hydrogel responded to 0.3 W/cm² ultrasound irradiation for 30 s (Figure 4D). The concentration of lidocaine increased as the ultrasound was turned on, while lidocaine was no longer released from the Lido-PPIX@ER hydrogel when the power was turned off. The effect of ultrasound on the morphology change of Lido-PPIX@ER was examined by SEM (Figure 4E). With the power on, the Lido-PPIX@ER showed an irregular morphology, and morphological changes of ER were observed facilitating lidocaine release.

Unsurprisingly, the Lido-PPIX@ER hydrogel maintained its bioactivity even after 9 d in PBS, representing a crucial property of Lido-PPIX@ER for postoperative pain management (Figure 4F). The Lido concentration in the supernatant was very low in the first 9 d, indicating that most of the Lido was stored inside the ERs and would not be released into PBS. On Day 9, the remaining Lido-PPIX@ER hydrogel was treated with ultrasound. The Lido concentration in the suspension increased rapidly after 30 s.
Releasing mechanism of the Lido-PPIX@ER hydrogel

We expected that when the Lido-PPIX@ER hydrogel is irradiated by ultrasound, PPIX will produce ROS, which consequently destroy the integrity of the ER membrane, leading to Lido release. To confirm the ultrasound-triggered leakage of Lido, Lido release from the Lido-PPIX@ER hydrogel was monitored following ultrasound treatment (0.3 W/cm\(^2\), 30 s) (Figure 5A). Given that the lipid bilayer membrane of ERs would be damaged in the presence of accumulated ROS to release the packed drugs [27], the relationship between ultrasound treatment and ROS production was studied and is shown in Figure 5B.

The ROS concentration was directly related to ultrasound because PPIX generated singlet oxygen after triggering. Once the ultrasound was turned off, ROS were no longer produced, and the residual ROS could be scavenged by SOD and CAT, leading to ROS exhaustion in the hydrogel. Therefore, the ROS concentration showed pulsate changes with the laser on and off. The accumulated ROS promoted pore formation in the ER membrane, allowing Lido release. Likewise, ROS generation was stopped when ultrasound was turned off, leading to closure of the pores in the ER membrane and inhibited PPIX release.

Additionally, we evaluated changes in the malondialdehyde (MDA) levels in Lido-PPIX@ER as an indicator of oxidative stress (Figure 5C). The changes in the MDA and H\(_2\)O\(_2\) levels were consistent, reflecting ultrasound triggering.

Postoperative pain management in vivo

To investigate the possibility of the Lido-PPIX@ER hydrogel controlling postoperative pain with ultrasound triggering, we treated a postoperative pain rat model with the Lido-PPIX@ER hydrogel. First, the mean serum Lido concentration after free Lido (6 mg) or 1 mL of Lido-PPIX@ER hydrogel (containing 5.6 mg/mL of lidocaine) treatment must be evaluated. In the lidocaine (6 mg)-treated group, the mean serum lidocaine concentration steadily increased to 1790 ng/mL at 2 h after subcutaneous administration (Figure 6A). In the Lido-PPIX@ER hydrogel-treated group, the serum lidocaine concentration did not show a burst increase after ultrasound triggering (0.3 W/cm\(^2\), 30 s).

To further prove that the ultrasound-triggered Lido-PPIX@ER hydrogel could be used in postoperative pain management, mechanical hypersensitivity was observed 2 h after paw incision (Figure 6B). Subcutaneous administration of the Lido-PPIX@ER hydrogel produced antihypersensitivity effects compared with the control group (\(P > 0.05\)). We confirmed that the ultrasound course of lidocaine released by the Lido-PPIX@ER hydrogel in vivo was similar to that of free Lido to manage postoperative pain in the first 4 h.

As expected, examination of the residual Lido-PPIX@ER hydrogel removed from rats after one ultrasound-triggered (0.3 W/cm\(^2\), 30 s) in vivo treatment revealed that approximately 91% and 90% of the administered lidocaine remained at 4 h and 10 h, respectively (Figure 6C). Conversely, approximately 11% and 6% of the administered lidocaine remained at 4 h and 10 h, respectively, in the free Lido-treated
group. Thus, sufficient subcutaneous storage of the Lido-PPIX@ER hydrogel provides a favorable condition for long-term ultrasound-triggered postoperative pain management.

The on-demand release of Lido in postoperative pain management meets the needs of the most acute care. We next tested the on-demand release behavior of the Lido-PPIX@ER hydrogel under different ultrasound-triggered times. With increasing ultrasound-triggered time, the Lido concentration increased as expected (Figure 6D).

Ultrasound at 0.3 W/cm\(^2\) for 30 s for triggered release in the Lido-PPIX@ER hydrogel was optimal because it achieved a stable plasma concentration (Figure 6E). After surgery, severe pain continued for approximately 12 h and was relieved. To address this issue, ultrasound was triggered every 2 h in the first 12 h, every 4 h for the next 36 h, and then every 6 h until 72 h after surgery. Thus, the mean serum lidocaine concentration was steadily high initially and then decreased from 592 ng/ml at 12 h to 487 ng/ml at 18 h after the administration of the ultrasound-triggered time interval. Unsurprisingly, the mean serum lidocaine concentration from 48 h to 72 h after surgery decreased to a lower level. Naked Lido without protection, by contrast, can be cleared from organisms by 4-8 h after subcutaneous administration.

The paw withdrawal threshold changed with the mean serum lidocaine concentration (Figure 6F). The group treated perineurally with repeatedly ultrasound-triggered Lido-PPIX@ER hydrogel showed stable withdrawal thresholds at various time periods, higher concentrations at all time points after paw incision than the free Lido-treated group, and lasted approximately 72 h. However, the free lidocaine treatment group disappeared 4 h after paw incision, and the paw withdrawal thresholds were decreased to less than 4 g.

To better fit the needs of men with different pain thresholds, the effective time at different paw withdrawal thresholds was examined (Figure 6G). The Lido-PPIX@ER hydrogel controlled the paw withdrawal thresholds over 4 g or 10 g for approximately 48 h and 12 h compared with the free lidocaine-treated group (\(P < 0.001\)). Therefore, repeated administration of the Lido-PPIX@ER hydrogel meets the requirement to ensure sustained postoperative pain management.

Safety analysis

Next, to evaluate the potential health risks after treatment with the Lido-PPIX@ER hydrogel plus laser irradiation, the treated mice were euthanized on Days 5 and 15. The main organs, including the heart, liver, kidney, lung, and spleen tissues, were stained with hematoxylin and eosin (H&E) (Figure 7A).

To evaluate the \(in vivo\) degradability of the Lido-PPIX@ER hydrogel, the size of the resultant subcutaneous skin lump was monitored over time (not shown). We noticed that 15 d postinjection, no obvious skin protrusion was noticed, illustrating the complete degradation of the Lido-PPIX@ER hydrogel. From the H&E staining results of surrounding tissues at the site of subcutaneously injected Lido-
PPIX@ER hydrogel, the lesion region was covered with connective tissue after 15 d (Figure 7B). Collectively, the hydrogel provided structural support and exhibited self degradation in vivo.

Furthermore, analysis of liver function (ALP, ALT, and AST) and kidney function (BUN, Cr, and GLB) markers (Figure 7C) revealed that Lido-PPIX@ER hydrogel + ultrasound treatment did not cause hepatic or kidney damage. Therefore, the Lido-PPIX@ER hydrogel exhibits good biocompatibility in vivo.

**Discussion**

To maximize postoperative pain relief, enhance patient satisfaction, and facilitate postoperative rehabilitation, pain management is essential. Lidocaine has been used in clinical medicine for more than half a century, and multimodal lidocaine-containing products have proven effective to treat postoperative pain. However, lidocaine may induce nerve demyelination and contribute to the neurotoxicity of lidocaine, and multiple dosing delivery was used in the clinic using conventional intravenous administration. This presents a challenge, such as the requirement of skilled professionals, a situation that is not easily achievable for families. Studies specifically designed to address this issue are required. Sustained-release local anesthetics have been reported to treat postoperative pain [5]. The liposomal bupivacaine injectable suspension (EXPAREL®; Pacira Pharmaceuticals, Inc., USA) has received FDA Approval for infiltration into a surgical site to provide postoperative analgesia in adults based on clinical trials in which subjects had undergone bunion reaction [29] and hemorrhoidectomy [30], demonstrating efficacy for 36 h and 72 h, respectively. Furthermore, clinical trials of liposomal bupivacaine for epidural block [31], femoral nerve block [32], transversus abdominis plane block [33] and interscalene block [34] have been reported previously. However, different people have different pain thresholds or pain tolerance scores. Therefore, an effective treatment for postoperative pain should consider variable timing and intensity of anesthetics.

Generally, men show severe pain on the day after the operation. With the extension of the treatment time, the postoperative pain is reduced over time. Different people have different pain thresholds or pain tolerance scores. Relieving local pain as needed, allowing patients to control the timing and intensity, would be the excellent choice to maximize personalized postoperative pain. An ultrasound-triggerable, on-demand nerve block system allows control of the duration and intensity of nerve block simply using the duration and intensity of the ultrasound [4]. In the present study, ultrasound-triggered on-demand local anesthesia was reported, and the intensity and duration of local anesthesia were controlled by adjusting the intensity and duration of the ultrasound. The Lido-PPIX@ER hydrogel described here allowed an on-demand release of lidocaine from the subcutaneous lidocaine reservoir by remote ultrasound control without frequent injection. Thus, additional time for on-demand nerve blocks is allowed, leading to personalized anesthesia-free pain management.

Alternatively, a sufficient action time must be considered in its clinical application because patients undergoing major spine surgery frequently experience severe postoperative pain lasting more than 3 d. Here, we designed a large capacity lidocaine vector that controls the timing, intensity and duration of lidocaine to relieve postoperative pain. Recently, the erythrocyte membrane has been extensively studied.
to develop novel drug delivery systems to prolong the cyclic persistence of drugs. As “innate carriers,” erythrocytes have many unique characteristics, such as perfect biocompatibility, a long circulation half-life (approximately 120 d in humans), membrane flexibility and stability. In the present study, ER were used as lidocaine carriers because of their high drug loading capacities and long in vivo circulation features in vessels [27]. Furthermore, the presence of accumulated H$_2$O$_2$ caused the pores in the erythrocyte membrane to open rapidly. Considering that PPIX produces H$_2$O$_2$ when triggered by ultrasound, we describe the development of an ultrasound-triggered drug release platform (Lido-PPIX@ER hydrogel) for postoperative pain management. From the results in Figure 3, the drug release platform was very stable in vivo, providing a prerequisite to obtain ultrasound-triggered on-demand release behavior.

Ultrasound, as an integral part of drug-delivery modalities, has many attractive features, including simplicity and cost-effectiveness [35]. Sonication can be performed noninvasively, and ultrasound waves can be directed to deep locations for precise energy-deposition patterns [36, 37]. In early studies, microbubbles, which are clinically recognized as ultrasound contrast agents, were used to load therapeutic agents for effective tumor chemotherapy. However, the shortcomings of these gas-filled microbubbles prevent their widespread use in drug delivery. In the present study, the hypothesis that sonochemistry and ROS production played a major role in ultrasound-triggered cargo release is supported by the observation that PPIX-loaded ER produced more ROS, opening the ER phospholipid bilayer and triggering drug release. Ultrasound-induced cavitation can produce light (sonoluminescence), which activates the photosensitizer PPIX to produce ROS. Implosion of ultrasound-induced cavitation bubbles can also induce the formation of sonosensitizer-derived free radicals that generate ROS. These effects depend on inertial cavitation following insonation, which may be caused by the ultrasound conditions used here (0.3 W/cm$^2$). Therefore, we designed a novel multimode osmotic analgesia scheme for wound infiltration.

**Conclusion**

In this study, we report an injectable, remote ultrasound-induced lidocaine delivery system for postoperative pain management. The Lido-PPIX@ER hydrogel exhibited high lidocaine loading capacity with efficient ultrasound-triggered release of lidocaine, making it a potential delivery system for well-regulated postoperative pain. In vivo experiments in a postoperative pain model showed that a single injection of Lido-PPIX@ER hydrogel can effectively control the duration and intensity of nerve block by simply adjusting the duration and intensity of ultrasound. Therefore, we suggest that this delivery system is an effective strategy to reduce pain, remotely control pain, and offer timed and spatiotemporally controlled release of Lido to manage postoperative pain.

**Declarations**

**Ethics approval and consent to participate** The procedures used in our study were approved by the Committee of the Animal Research of Nantong University (20210421-072), and followed the guidelines
the Use of Animals in Research of the International Association for the Study of Pain and the directive of the European Parliament (2010/63/EU).

Availability of data and materials: Not applicable.

Consent for publication: Not applicable.

Competing interests: The authors declare that they have no competing interests.

Funding: This work was supported by the Clinical Frontier Technology Project of China Jiangsu Provincial Department of Science and Technology (BE2018669), the Health Research Funds of Nantong, China (2020JCC046).

Authors' contributions

J.P. Yang and X.H. Chen conceived the idea and designed the experiments. J.F. Zhang and Y. Yu, did the synthesis, characterization. H.R. Wang and G.S. Ma conducted the in vitro experiments, X.H. Chen, D. Wang, D.L. Xia, and H.Z. Cao did the in vivo analyses. X.H. Chen, J.F. Zhang, D.L. Xia, H.Z. Cao, and J.P. Yang analyzed all the data and wrote the manuscript. All the authors have proof-read this article and approved its publication.

Acknowledgements: Not applicable.

References

[1] J.M. Joseph, D. Gori, C. Curtin, J. Hah, V.T. Ho, S.M. Asch, T. Hernandez-Boussard, (2021) Gaps in standardized postoperative pain management quality measures: A systematic review, Surgery. doi:10.1016/j.surg.2021.08.004.

[2] X. Gao, X. Xin, Z. Li, W. Zhang, (2021) Predicting postoperative pain following root canal treatment by using artificial neural network evaluation, Scientific reports; 11: 17243. doi:10.1038/s41598-021-96777-8.

[3] Y. Wang, X. Wang, K. Zhang, (2020) Effects of transversus abdominis plane block versus quadratus lumborum block on postoperative analgesia: a meta-analysis of randomized controlled trials, BMC anesthesiology; 20: 103. doi:10.1186/s12871-020-01000-2.

[4] A.Y. Rwei, J.L. Paris, B. Wang, W. Wang, C.D. Axon, M. Vallet-Regi, R. Langer, D.S. Kohane, (2017) Ultrasound-triggered local anaesthesia, Nat Biomed Eng; 1: 644-653. doi:10.1038/s41551-017-0117-6.

[5] Z. Wang, H. Huang, S. Yang, S. Huang, J. Guo, Q. Tang, F. Qi, (2016) Long-term effect of ropivacaine nanoparticles for sciatic nerve block on postoperative pain in rats, International journal of nanomedicine; 11: 2081-90. doi:10.2147/IJN.S101563.
[6] M. Tobe, H. Obata, T. Suto, H. Yokoo, Y. Nakazato, Y. Tabata, S. Saito, (2010) Long-term effect of sciatic nerve block with slow-release lidocaine in a rat model of postoperative pain, Anesthesiology; 112: 1473-81. doi:10.1097/ALN.0b013e3181d4f66f.

[7] S.J. Park, H.S. Kim, G.W. Yim, (2021) Comparison of Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) and Laparoendoscopic Single-Site (LESS) Hysterectomy on Postoperative Pain Reduction: A Randomized Pilot Study, Pain Ther. doi:10.1007/s40122-021-00300-w.

[8] P. Beaulieu, (2021) Cannabinoids and acute/postoperative pain management, Pain; 162: 2309. doi:10.1016/j.pain.2021.03.011.

[9] S.L. Pedersen, T.H. Huynh, P. Poschko, A.S. Fruegaard, M.T. Jarlstad Olesen, Y. Chen, H. Birkedal, G. Subbiahdoss, E. Reimhult, J. Thogersen, A.N. Zelikin, (2020) Remotely Triggered Liquefaction of Hydrogel Materials, ACS nano; 14: 9145-9155. doi:10.1021/acsnano.0c04522.

[10] J.K. Park, K. Nan, H. Luan, N. Zheng, S. Zhao, H. Zhang, X. Cheng, H. Wang, K. Li, T. Xie, Y. Huang, Y. Zhang, S. Kim, J.A. Rogers, (2019) Remotely Triggered Assembly of 3D Mesostructures Through Shape-Memory Effects, Advanced materials; 31: e1905715. doi:10.1002/adma.201905715.

[11] M. Raoof, B.T. Cisneros, A. Guven, S. Phounsavath, S.J. Corr, L.J. Wilson, S.A. Curley, (2013) Remotely triggered cisplatin release from carbon nanocapsules by radiofrequency fields, Biomaterials; 34: 1862-9. doi:10.1016/j.biomaterials.2012.11.033.

[12] T. van Rooij, I. Skachkov, I. Beekers, K.R. Lattwein, J.D. Voorneveld, T.J.A. Kokhuis, D. Bera, Y. Luan, A.F.W. van der Steen, N. de Jong, K. Kooiman, (2021) Corrigendum to "Viability of endothelial cells after ultrasound-mediated sonoporation: Influence of targeting, oscillation, and displacement of microbubbles" [Journal of Controlled Release 238 (2016) 197-211], Journal of controlled release : official journal of the Controlled Release Society; 332: 502. doi:10.1016/j.jconrel.2021.03.011.

[13] Y. Jing, Z. Xiu-Juan, C. Hong-Jiao, C. Zhi-Kui, Q. Qing-Fu, X. En-Sheng, L. Li-Wu, (2019) Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts, Journal of cancer research and clinical oncology; 145: 1191-1200. doi:10.1007/s00432-019-02866-7.

[14] T. Singh, I.S. Castellanos, S. Haar, A. Klimas, E. Entcheva, T. Salvador, D.C. Bhowmick, J. Cohen, K. Cleary, A. Jeremic, V. Zderic, (2018) Ultrasound-Induced Insulin Release as a Potential Novel Treatment for Type 2 Diabetes Mellitus, Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference; 2018: 6060-6063. doi:10.1109/EMBC.2018.8513687.

[15] N. Kuls, R. Trujanovic, P.E. Otero, M.P. Larenza-Menzies, (2020) Ultrasound-Guided Transversus Abdominis Plane Block in Shetland Ponies: A Description of a Three-Point Injection Technique and
Evaluation of Potential Analgesic Effects, Journal of equine veterinary science; 90: 102994. doi:10.1016/j.jevs.2020.102994.

[16] X. Song, L. Feng, C. Liang, K. Yang, Z. Liu, (2016) Ultrasound Triggered Tumor Oxygenation with Oxygen-Shuttle Nanoperfluorocarbon to Overcome Hypoxia-Associated Resistance in Cancer Therapies, Nano letters; 16: 6145-6153. doi:10.1021/acsnanolett.6b02365.

[17] D. Xia, P. Xu, X. Luo, J. Zhu, H. Gu, D. Huo, Y. Hu, (2019) Overcoming Hypoxia by Multistage Nanoparticle Delivery System to Inhibit Mitochondrial Respiration for Photodynamic Therapy, Advanced functional materials; 29: 1807294. doi:10.1002/adfm.201807294.

[18] A. Al-Achi, R. Greenwood, (1998) Erythrocytes as oral delivery systems for human insulin, Drug development and industrial pharmacy; 24: 67-72. doi:10.3109/03639049809082354.

[19] M.E. Favretto, J.C. Cluitmans, G.J. Bosman, R. Brock, (2013) Human erythrocytes as drug carriers: loading efficiency and side effects of hypotonic dialysis, chlorpromazine treatment and fusion with liposomes, Journal of controlled release : official journal of the Controlled Release Society; 170: 343-51. doi:10.1016/j.jconrel.2013.05.032.

[20] M. Hamidi, N. Zarei, A.H. Zarrin, S. Mohammadi-Samani, (2007) Preparation and in vitro characterization of carrier erythrocytes for vaccine delivery, International journal of pharmaceutics; 338: 70-8. doi:10.1016/j.ijpharm.2007.01.025.

[21] L. Wang, C. Ren, Y. Li, C. Gao, N. Li, H. Li, D. Wu, X. He, C. Xia, X. Ji, (2021) Remote ischemic conditioning enhances oxygen supply to ischemic brain tissue in a mouse model of stroke: Role of elevated 2,3-biphosphoglycerate in erythrocytes, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism; 41: 1277-1290. doi:10.1177/0271678X20952264.

[22] C. Strauss, E. Brix, A. Anker, L. Prantl, V. Brebant, T. Aung, (2017) Perfusion control of a partial revascularized hand via application of Indocyanine green (ICG) and Near-infrared Fluorescence Imaging, Clin Hemorheol Microcirc; 67: 215-219. doi:10.3233/CH-179202.

[23] C.G. Millán, M.a.L.S. Marinero, A.Z. Castañeda, J.M. Lanao, (2004) Drug, enzyme and peptide delivery using erythrocytes as carriers, Journal of Controlled Release; 95: 27-49. doi:10.1016/j.jconrel.2003.11.018.

[24] L. Chronopoulou, A.R. Togna, G. Guarguaglini, G. Masci, F. Giammaruco, G.I. Togna, C. Palocci, (2012) Self-assembling peptide hydrogels promote microglial cells proliferation and NGF production, Soft Matter; 8. doi:10.1039/c2sm25528f.

[25] S.R. Chaplan, F.W. Bach, J.W. Pogrel, J.M. Chung, T.L. Yaksh, (1994) Quantitative assessment of tactile allodynia in the rat paw, Journal of neuroscience methods; 53: 55-63. doi:10.1016/0165-
[26] J. Wang, C. Yao, B. Shen, X. Zhu, Y. Li, L. Shi, Y. Zhang, J. Liu, Y. Wang, L. Sun, (2019) Upconversion-Magnetic Carbon Sphere for Near Infrared Light-Triggered Bioimaging and Photothermal Therapy, Thera-no; 9: 608-619. doi:10.7150/thno.27952.

[27] D. Xia, H. He, Y. Wang, K. Wang, H. Guo, P. Xu, Y. Hu, (2018) Ultrafast glucose-responsive, high loading capacity erythrocyte to self-regulate the release of insulin, Acta biomaterialia; 69: 301-312. doi:10.1016/j.actbio.2018.01.029.

[28] M. Rose, D.C. Currow, (2009) The Need for Chemical Compatibility Studies of Subcutaneous Medication Combinations Used in Palliative Care, J. Pain Palliative Care Pharmacotherapy; 23: 223-230. doi:10.1080/15360280903098382.

[29] M. Golf, S.E. Daniels, E. Onel, (2011) A phase 3, randomized, placebo-controlled trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy, Advances in therapy; 28: 776-88. doi:10.1007/s12325-011-0052-y.

[30] S.R. Gorne, E. Onel, G. Patou, Z.V. Krivokapic, (2011) Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial, Diseases of the colon and rectum; 54: 1552-9. doi:10.1097/DCR.0b013e318232d4c1.

[31] E.R. Viscusi, K.A. Candiotti, E. Onel, M. Morren, G.L. Ludbrook, (2012) The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers, Regional anesthesia and pain medicine; 37: 616-22. doi:10.1097/AAP.0b013e318269d29e.

[32] J.W. Surdam, D.J. Licini, N.T. Baynes, B.R. Arce, (2015) The use of exparel (liposomal bupivacaine) to manage postoperative pain in unilateral total knee arthroplasty patients, The Journal of arthroplasty; 30: 325-9. doi:10.1016/j.arth.2014.09.004.

[33] M. Fayeziadeh, A. Majumder, R. Neupane, H.L. Elliott, Y.W. Novitsky, (2016) Efficacy of transversus abdominis plane block with liposomal bupivacaine during open abdominal wall reconstruction, American journal of surgery; 212: 399-405. doi:10.1016/j.amjsurg.2015.12.026.

[34] S. Namdari, T. Nicholson, J. Abboud, M. Lazarus, D. Steinberg, G. Williams, (2017) Randomized Controlled Trial of Interscalene Block Compared with Injectable Liposomal Bupivacaine in Shoulder Arthroplasty, The Journal of bone and joint surgery. American volume; 99: 550-556. doi:10.2106/JBJS.16.00296.

[35] M. Covotta, C. Claroni, M. Costantini, G. Torregiani, L. Pelagalli, A. Zinilli, E. Forastiere, (2020) The Effects of Ultrasound-Guided Transversus Abdominis Plane Block on Acute and Chronic Postsurgical
Pain After Robotic Partial Nephrectomy: A Prospective Randomized Clinical Trial, Pain medicine; 21: 378-386. doi:10.1093/pm/pnz214.

[36] X. Mi, B. Zou, P. Rashidi, R. Baharloo, R.B. Fillingim, M.R. Wallace, P.L. Crispen, H.K. Parvataneni, H.A. Prieto, C.F. Gray, T.N. Machuca, S.J. Hughes, G.J.A. Murad, E. Thomas, A. Iqbal, P.J. Tighe, G. Temporal Postoperative Pain Signatures, (2021) Effects of Patient and Surgery Characteristics on Persistent Postoperative Pain: A Mediation Analysis, The Clinical journal of pain. doi:10.1097/AJP.00000000000000979.

[37] J. de la Fuente, J.F. Aramendi, J.M. Ibanez, M. Blasi, A. Vazquez, J.J. Aurrekoetxea, F. Davila, (2021) Minimally invasive ultrasound-guided vs open release for carpal tunnel syndrome in working population: A randomized controlled trial, Journal of clinical ultrasound : JCU; 49: 693-703. doi:10.1002/jcu.23019.

**Scheme**

Please see the Supplementary Files for the Scheme 1.

**Figures**
Figure 1

Construction of Lido-PPIX@ER. (A) SEM images of Lido-PPIX@ER during hypotonic, hypertonic or PBS treatment. (B) Schematic diagram of phospholipid bilayer changes during hypotonic, hypertonic or PBS treatment. (C) Relationship between the initial Lido concentration and loading content. (D) Effect of dialysis duration on the Lido loading content. (E) Relationship between the temperature and loading content.
Figure 2

Structure of Lido-PPIX@ER. (A) Relationship between the initial PPIX concentration and loading content. (B) Confocal images of FITC-labeled INS (green), PPIX (red), and merged fluorescence. (C) Hematological parameters of normal blood and Lido-PPIX@ER, including red blood cells (RBCs), hematocrit (HCT), mean corpuscular volume (MCV), red cell distribution width (RDW), hemoglobin (Hb), and mean corpuscular hemoglobin (MCH).
Figure 3

Characterization of the Lido-PPIX@ER hydrogel. (A) Rheology properties of PFL-catalyzed Fmoc-Phe3. (B) Photographs showing the gelation behavior of the Lido-PPIX@ER hydrogel after adding PFL for 2 and 10 min and photograph of the injectable Lido-PPIX@ER hydrogel. (C) Photograph of peptide hydrogel in vivo. The peptide hydrogel was subcutaneously injected within 2 min. Ten minutes later, the mixture and PFL could also shift from liquid to a homogeneous gel state in vivo. (D) Volume change curve of the Lido-PPIX@ER hydrogel in PBS at 37 °C. (E) Weight fraction in per cent vs. time of Lido-PPIX@ER hydrogel in PBS at 37 °C. (G) Stability of Lido-PPIX@ER hydrogel in vitro. (H) Immunohistochemical staining for f4/80 to identify infiltrated macrophages in the subcutaneous tissues. The experiment was repeated at least three times.
Figure 4

Ultrasound-triggered release behavior of the Lido-PPIX@ER hydrogel. (A) In vitro lidocaine release from the Lido-PPIX@ER hydrogel at increasing ultrasound power at 37 °C. (B) In vitro lidocaine release from the Lido@ER hydrogel or Lido-PPIX@ER hydrogel with or without laser intensities at 37 °C (0.3 W/cm², 60 s). (C) Release profile of lidocaine from 1.0 mL of Lido-PPIX@ER hydrogel during continuous ultrasound triggering. (D) In vitro release profile of lidocaine when the ultrasound was cyclically varied between on and off for several repetitions. (E) Morphological changes of Lido-PPIX@ER during “on-off” lidocaine release. (F) Ultrasound-triggered release behavior of the Lido-PPIX@ER hydrogel after storage in PBS at 4 °C for 9 d.
**Figure 5**

Release mechanism of the Lido-PPIX@ER hydrogel under ultrasound. (A) Schematic representation showing the ultrasound-regulated release of lidocaine from the Lido-PPIX@ER hydrogel. (B) Concentration profile of singlet oxygen with ultrasound (0.3 W/cm²) in the on/off state. (C) MDA concentration changes of the Lido-PPIX@ER hydrogel under ultrasound regulation (on-off state) at 37 °C.

**Figure 6**

Effects of managing postoperative pain in vivo. (A) Change curve of the serum Lido concentration and (B) paw withdrawal threshold (2 h after surgery) after one ultrasound trigger. (C) Ratio of the remaining lidocaine in free lidocaine and Lido-PPIX@ER hydrogel after one ultrasound-triggered removal from the administration site in rats. (D) Duration of ultrasound-triggered lidocaine release and effect of pain relief application in the rat model of postoperative pain in the Lido-PPIX@ER hydrogel-treated group. (E) Change curve of the serum Lido concentration and (F) the hind paw withdrawal thresholds after on-demand ultrasound triggering in the Lido-PPIX@ER hydrogel group (triggered for every 2 h in the first 12 h
and every 4 h for the next 36 h, and then every 6 h until 72 h after surgery). (G) Effective time at different paw withdrawal thresholds in the ultrasound-triggered Lido-PPIX@ER hydrogel group. ***, P<0.001.

**Figure 7**

Biosafety of the Lido-PPIX@ER hydrogel in vivo. (A) Images of H&E staining after treatment with the Lido-PPIX@ER hydrogel. (B) H&E-stained sections of surrounding tissues at the site of subcutaneously injected Lido-PPIX@ER hydrogel. Scale bar = 100 μm. (C) Kidney function (BUN, Cr, and GLB) and the levels of liver (ALP, ALT, and AST) markers on Days 1, 3, 5 and 15 in the control and Lido-PPIX@ER hydrogel treatment groups.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- scheme1.jpg
- renamed3a415.pdf